Literature DB >> 1325994

Bromocriptine inhibits pro-opiomelanocortin mRNA and ACTH precursor secretion in small cell lung cancer cell lines.

W E Farrell1, A J Clark, M F Stewart, S R Crosby, A White.   

Abstract

We have previously reported that a human small cell lung cancer (SCLC) cell line (COR L103) that expresses the proopiomelanocortin (POMC) gene and secretes ACTH precursor peptides is relatively resistant to glucocorticoid regulation. Using this model, we have now examined alternative regulatory mechanisms of the POMC gene and found that both the mRNA and ACTH precursor peptides were stimulated four- and two-fold, respectively, after 48 h incubation with db-cAMP. Next, we examined the dopamine agonist, bromocriptine, which acts predominantly through D2 receptors linked to adenyl cyclase to cause a reduction in intracellular cAMP. Bromocriptine suppressed cAMP levels and inhibited precursor peptide secretion within 24 h in a dose-dependent manner (0.15-15 microM). At the highest dose, peptide secretion was inhibited from 95 to 53 pmol/mg protein, and POMC mRNA was reduced by 50%, while beta-actin mRNA remained unchanged. This effect could not be mimicked by incubation of cells with the alpha-adrenergic antagonist, phenoxybenzamine, suggesting that the alpha-adrenergic effects of bromocriptine were not responsible for this observation. These cells also secrete estradiol, but the secretory rate was unaffected by bromocriptine, suggesting, with the beta-actin data, that the POMC inhibition was not a cytotoxic effect. No recovery in precursor peptide secretion was seen in a 48-h period after the removal of bromocriptine. However, when the postchallenge incubation was extended to 8 d, there was a recovery in secretory potential between day 3 and day 8 and normal growth kinetics in the 4 d after removal of the drug. In contrast to these findings, the mouse corticotroph cell line, AtT20, showed no response to bromocriptine, in keeping with reports that this agonist has no effect on anterior lobe corticotrophs. We conclude that bromocriptine effectively inhibits POMC expression in SCLC cells, and that this phenomenon might be of useful clinical application.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325994      PMCID: PMC329920          DOI: 10.1172/JCI115941

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

Review 1.  Ectopic hormone syndromes.

Authors:  P C Kohler; D L Trump
Journal:  Cancer Invest       Date:  1986       Impact factor: 2.176

Review 2.  Receptor-mediated actions of corticotropin-releasing factor in pituitary gland and nervous system.

Authors:  G Aguilera; P C Wynn; J P Harwood; R L Hauger; M A Millan; C Grewe; K J Catt
Journal:  Neuroendocrinology       Date:  1986       Impact factor: 4.914

3.  A study of corticotroph adenomas in Cushing's disease: no evidence of intermediate lobe origin.

Authors:  A M McNicol; G M Teasdale; G H Beastall
Journal:  Clin Endocrinol (Oxf)       Date:  1986-06       Impact factor: 3.478

Review 4.  Clinical and laboratory studies of ectopic humoral syndromes.

Authors:  G W Liddle; W E Nicholson; D P Island; D N Orth; K Abe; S C Lowder
Journal:  Recent Prog Horm Res       Date:  1969

5.  Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.

Authors:  P S Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

6.  Plasma bombesin concentrations in patients with extensive small cell carcinoma of the lung.

Authors:  C B Pert; U K Schumacher
Journal:  Lancet       Date:  1982-02-27       Impact factor: 79.321

7.  Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: differences in the regulation of hormone secretion.

Authors:  S W Lamberts; S A de Lange; S Z Stefanko
Journal:  J Clin Endocrinol Metab       Date:  1982-02       Impact factor: 5.958

8.  Hormone production by cultures of small-cell carcinoma of the lung.

Authors:  G D Sorenson; O S Pettengill; T Brinck-Johnsen; C C Cate; L H Maurer
Journal:  Cancer       Date:  1981-03-15       Impact factor: 6.860

9.  The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing's disease and Nelson's syndrome.

Authors:  S W Lamberts; J G Klijn; M de Quijada; H A Timmermans; P Uitterlinden; F H de Jong; J C Birkenhäger
Journal:  J Clin Endocrinol Metab       Date:  1980-08       Impact factor: 5.958

10.  Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer.

Authors:  F Cuttitta; D N Carney; J Mulshine; T W Moody; J Fedorko; A Fischler; J D Minna
Journal:  Nature       Date:  1985 Aug 29-Sep 4       Impact factor: 49.962

View more
  8 in total

Review 1.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

Review 2.  Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome.

Authors:  C de Bruin; R A Feelders; S W J Lamberts; L J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-19       Impact factor: 6.514

3.  Long-term quiescence of ectopic Cushing's syndrome caused by pulmonary neuroendocrine tumor (typical carcinoid) and tumorlets: spontaneous remission or therapeutic effect of bromocriptine?

Authors:  G Francia; M V Davì; E Montresor; C Colato; M Ferdeghini; V Lo Cascio
Journal:  J Endocrinol Invest       Date:  2006-04       Impact factor: 5.467

Review 4.  Current concepts in neuroendocrine cancer metabolism.

Authors:  Joseph E Ippolito
Journal:  Pituitary       Date:  2006       Impact factor: 3.599

5.  Follistatin is a novel biomarker for lung adenocarcinoma in humans.

Authors:  Fangfang Chen; Ping Ren; Ye Feng; Haiyan Liu; Yang Sun; Zhonghui Liu; Jingyan Ge; Xueling Cui
Journal:  PLoS One       Date:  2014-10-27       Impact factor: 3.240

6.  Co-Administration of Curcumin and Bromocriptine Nano-liposomes for Induction of Apoptosis in Lung Cancer Cells

Authors:  Mojgan Sheikhpour; Majid Sadeghizadeh; Fatemeh Yazdian; Ali Mansoori; Hassan Asadi; Abolfazl Movafagh; Seyed Sadegh Shahraeini
Journal:  Iran Biomed J       Date:  2019-08-28

Review 7.  The dopaminergic control of Cushing's syndrome.

Authors:  R Pivonello; C Pivonello; C Simeoli; M C De Martino; A Colao
Journal:  J Endocrinol Invest       Date:  2022-04-23       Impact factor: 5.467

Review 8.  Dopamine Agonists for Pituitary Adenomas.

Authors:  Odelia Cooper; Yona Greenman
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-21       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.